trial

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

NCTId NCT02824055
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 33 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2017-04-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
33 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2016-06-27
Primary completion
2017-04-24
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
RO5545965

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

3 total
Garden Grove, United StatesGlendale, United StatesSt Louis, United States

Facts & assertions

4 sourced
Enrollment
33
Phase
PHASE1
Primary Completion Date
2017-04-24
Status
COMPLETED
relationships
The graph out of here
drug
RO5545965
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication